Chakri Lokapriya highlights a selective approach toward pharma, favoring Cipla and Piramal for potential gains due to specific catalysts like FDA approvals. He recommends buying IT stocks like HCL Tech and Mphasis amid market dips, driven by robust cloud computing growth predictions. Trent and Titan continue to show strong urban consumption trends.
